Inhibitors against CDK4/6, which induce G1 to S phase cell cycle arrest, have demonstrated therapeutic efficacy in both endocrine therapy naïve and resistant ER+ breast cancer [9–11]. This evidence concerns the gene CDK4 and breast cancer.